Hi Lisa,
    Krista Rubin gave an excellent overview of targeted therapy in the adjuvant setting (from the COMBI-AD Phase 3 trial) in the immunotherapy section above. In terms of practice change, this would call for BRAF testing in all Stage III patients which is not necessarily the standard approach for all practices. This is a very exciting time in melanoma!

    Latest Activity